Tenormin I.V. Related Published Studies
Well-designed clinical trials related to Tenormin I.V. (Atenolol)
Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. [2008.08]
The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial. [2008.07]
Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. [2008.02]
Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. [2007.10]
Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. [2007.05]
An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. [2007.05]
The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients. [2007.01]
Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy results from the swedish irbesartan left ventricular hypertrophy investigation vs atenolol (SILVHIA). Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). [2006.09]
Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension. [2006.09]
Effect of rifampicin on the pharmacokinetics of atenolol. [2006.06]
How can we block sympathetic overactivity? Effects of rilmenidine and atenolol in overweight hypertensive patients. [2006.06]
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. [2006.03]
Effects of atenolol and losartan on baroreflex sensitivity and heart rate variability in uncomplicated essential hypertension. [2006.02]
Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. [2006.02]
Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. [2006]
Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy). [2006]
Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters? [2005.12]
Effect of itraconazole on the pharmacokinetics of atenolol. [2005.12]
Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients. [2005.12]
Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. [2005.12]
Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. [2005.11]
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. [2005.09.10]
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. [2005.09.06]
Survival times in dogs with severe subvalvular aortic stenosis treated with balloon valvuloplasty or atenolol. [2005.08.01]
Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease. [2005.08]
Effects of orange juice on the pharmacokinetics of atenolol. [2005.07]
Carotid wall composition in hypertensive patients after 4-year treatment with lacidipine or atenolol: an echoreflectivity study. [2005.06]
[Metoprolol and atenolol in mild-to-moderate chronic heart failure: comparative study] [2005.05]
Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). [2005.05]
Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. [2005.05]
Effects of atenolol and propranolol on platelet aggregation in moderate essential hypertension: randomized crossover trial. [2005.04]
Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. [2005.04]
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. [2005.03]
Biopharmaceutical evaluation of oral tablet Atenolol (100 and 50 mg) on local population. [2005.01]
Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. [2005]
A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients. [2005]
Acute hemodynamic effects of amlodipine 15 days after a myocardial infarction in normotensive patients treated with atenolol. [1997.04]
[Atenolol i.v. in the acute phase of AMI: the indications, contraindications and interactions with thrombolytic drugs in the GISSI-2 study. The GISSI-2 Researchers. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico] [1995.03]
[The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus] [1991.04]
Comparative effects of atenolol and cicloprolol on cardiac performance in coronary heart disease. [1989.01]
Beta 1-adrenoceptor selectivity of single oral doses of bisoprolol and atenolol. [1988.09]
Well-designed clinical trials possibly related to Tenormin I.V. (Atenolol)
The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker. [2008.08]
Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. [2008.05]
Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. [2008.04]
Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. [2008.03]
Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. [2008.02]
Impact of the preintervention rate of renal function decline on outcome of renoprotective intervention. [2008.01]
Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. [2007.11]
Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. [2007.09.04]
Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study). [2007.09.01]
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. [2007.08.14]
Noninvasive pulse waveform analysis in clinical trials: similarity of two methods for calculating aortic systolic pressure. [2007.08]
Effects of "newer" and "older" antihypertensive drugs on hemorrheological, platelet, and endothelial factors a substudy of the anglo-scandinavian cardiac outcomes trial. [2007.06]
Similar effects of treatment on central and brachial blood pressures in older hypertensive subjects in the Second Australian National Blood Pressure Trial. [2007.06]
Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. [2007.05]
Expedited blood pressure control with initial angiotensin II antagonist/diuretic therapy compared with stepped-care therapy in patients with ambulatory systolic hypertension. [2007.04]
Effect of Sulfhydryl and non-Sulfhydryl Angiotensin-Converting Enzyme Inhibitors on Endothelial Function in Essential Hypertensive Patients. [2007.04]
Comparative effects of conventional B-blockers and nebivolol on psychomotor performances in healthy volunteers: a preliminary report. [2007.04]
Lercanidipine in the treatment of hypertension. [2007.03]
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. [2007.02]
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial. [2007.02]
Low-dose quadruple antihypertensive combination: more efficacious than individual agents--a preliminary report. [2007.02]
Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. [2007.02]
Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials. [2007.01.01]
Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. [2007.01]
Large and small artery endothelial function in patients with essential hypertension--effect of ACE inhibition and beta-blockade. [2007]
Impact of beta-blocker treatment and nutritional status on glycemic response during exercise in patients with type 2 diabetes. [2007]
Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. [2006.12]
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). [2006.10.01]
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. [2006.09.13]
Dose-dependent effect of dobutamine on chemoreflex activity in healthy volunteers. [2006.09]
N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy. [2006.08]
Rate control and quality of life in patients with permanent atrial fibrillation: the Quality of Life and Atrial Fibrillation (QOLAF) Study. [2006.08]
Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. [2006.08]
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? [2006.06.20]
Lessons learned from a randomised controlled study of perioperative beta blockade in high risk patients undergoing emergency surgery. [2006.06]
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. [2006.05.09]
The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. [2006.05]
Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials. [2006.05]
The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects. [2006.05]
Arterial hypertension and stroke prevention: an update. [2006.04]
Depressive symptoms in coronary artery disease patients after hypertension treatment. [2006.04]
Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. [2006.03.28]
Cost implications of development of diabetes in the ALPINE study. [2006.03]
Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. [2006.01]
Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. [2006.01]
The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. [2006]
The ASCOT trial: clarifying the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension. [2006]
Heart rate slowing versus other pharmacological antianginal strategies. [2006]
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. [2005.12.01]
Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy. [2005.11]
Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). [2005.09.01]
Investigation of the effects of physiological and vasodilation-induced autonomic activation on the QTc Interval in healthy male subjects. [2005.07]
Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region. [2005.05]
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. [2005.04.19]
Khat chewing and arterial blood pressure. A randomized controlled clinical trial of alpha-1 and selective beta-1 adrenoceptor blockade. [2005.04]
Optimising the use of beta-adrenoceptor antagonists in coronary artery disease. [2005]
Electrophysiologic effects of amlodipine vs. diltiazem in patients with coronary artery disease and beta-blocking therapy. [1994.08]
Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: I. Effects on blood pressure, heart rate and pressor responsiveness in normotensive subjects. [1991.11]
Pharmacodynamic monitoring during acute intervention in ischaemic heart disease using a new echo-Doppler device. [1990.06]
Epinephrine-induced enhancement of sympathetic activity in humans: inhibition by nonselective as well as beta 1-selective beta-adrenoceptor blockade. [1990.04]
|
